摘要
目的探讨吡格列酮对2型糖尿病患者颈动脉内膜中膜厚度的影响。方法68名2型糖尿病患者,随机双盲分为吡格列酮组(n=34)和安慰剂组(n=34),治疗3个月后,应用B超技术检测患者颈动脉内膜中膜厚度,并检测两组患者服药前后餐后2 h血糖、糖基化血红蛋白、血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平。结果与安慰剂组比较,吡格列酮治疗后颈动脉内膜中膜厚度变小(P<0.01),餐后2 h血糖、糖基化血红蛋白和甘油三酯水平明显下降(P<0.01),高密度脂蛋白胆固醇水平明显增加(P<0.01),两组血清总胆固醇、低密度脂蛋白胆固醇在治疗后无显著性差异。吡格列酮治疗后颈动脉内膜中膜厚度变化值与低密度脂蛋白胆固醇和高密度脂蛋白胆固醇的变化值密切相关(P<0.01)。结论吡格列酮能够显著降低2型糖尿病患者颈动脉内膜中膜厚度,有益于改善2型糖尿病患者大血管并发症。
Aim To study the effects of pioglitazone on intima-medial thickness（IMT） of carotid artery in type 2 diabetic mellitus （T2DM） patients. Methods T2DM patients （n=68） were divided into pioglitazone group （n=3d） and placebo group（n=34） by the rule of random and double-blind. The IMT of carotid artery was detected by B-mode ultrasound 3 months later. After 3 months treatment, postprandial blood glucose （PBG）, HbAle, total cholesterol （ TC ）, triglyceride （ TG ）, low density lipoprotein cholesterol （LDLC）and high density lipoprotein cholesterol （HDLC）were measured. rotid artery in pioglitazone group was significantly lower than that in placebo group （ p 〈 0.01 ）. Compared with placebo group, the serum levels of PBG, HbA1C and TG in pioglitazone treatmem group were significantly lower （P 〈 0.01） and the level of HDLC was markedly inereased （P〈0.01）. No signifieant difference of TC and LDLC was found betwecn the two groups . The decreased IMT of carotid artery was sign/ficanfly associated with chang of LDLC and HDLC. Conclusion Pioglitazone could signiticanfly reduce IMT of carotid artery in T2 DM patients and have positive effects on improving vascular complications of T2 DM patients.
出处
《中国动脉硬化杂志》
CAS
CSCD
2005年第5期627-629,共3页
Chinese Journal of Arteriosclerosis
